reports
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Devel...
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it will present at the 7th Obesity & NASH Drug Development Summit taking place November 27 – 29, 2023 in Boston. Scott Campbell,...
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness w...
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease - Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test - “These findings presented today at AASLD The Liver Meeting® confirm that rencofilstat’s novel mechanism of action represents a fresh approach to the treatment of severe liver disease.” (Patrick Mayo, PhD, Hepion’s Senior VP, Cl...
Hepion Pharmaceuticals Schedules Conference Call to Review Additional ...
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023 EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases,...
Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity...
Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model - Rencofilstat, but not sofosbuvir or velpatasvir, significantly suppressed tumor growth - EDISON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced the publication of a ...
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offeri...
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules EDISON, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it has entered into a securities purchase agreement with a healthcare-focused...
Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare...
Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that its Chief Executive Officer, Robert Foster, PharmD, PhD, will participate in a panel discussion during the 2023 Cantor Global Healthcare...
New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Ren...
New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program - 850 cancer cell lines screened in Broad Institute’s PRISM lab - - Rencofilstat active on 220 cancer cell lines spanning 86% of cancer types – EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chr...
Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Ca...
Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer - Research study demonstrates regulation of chromatin structure and cancer gene expression – - Findings to augment clinical trial in liver cancer - EDISON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today ...
Rencofilstat Produces Positive Outcomes in Translational Study on Idio...
Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis – Proteomics analysis showed that rencofilstat improved aberrant protein profiles in IPF tissues – – Superior effects of rencofilstat alone and in combination with pirfenidone and nintedanib – EDISON, N.J., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic ...
Hepion Pharmaceuticals Announces Management Changes
Hepion Pharmaceuticals Announces Management Changes EDISON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, announced that Stephen Harrison, M.D., has been appointed as Consultant Medical Director. Dr. Harrison, the current Chairman of Hepion’s Scientific Advisory Board (“SAB”), succeeds Todd...
Hepion Pharmaceuticals to Present Two Posters at EASL International Li...
Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023 - Preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcriptome and lipidome toward NASH resolution – - Cyclophilin B inhibition confirmed as an important target for treatment of NAFLD/NASH - EDISON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence (“AI”)-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (...
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Ph...
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat Completion of Enrollment Remains on Track for Q1, 2024 EDISON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that the Data and Safety Monitoring Board (“...
Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual S...
Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences EDISON, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence (“AI”)-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, announces that its Senior Vice President for Clinical Pharmacology and Analytics, Patrick Mayo, PhD, and its Quan...
Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary...
Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers - Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat’s direct antifibrotic mode of action; increases confidence for reductions in fibrosis in ongoing Phase 2b ‘ASCEND-NASH’ paired biopsy trial - EDISON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on ...
Hepion Pharmaceuticals Schedules Conference Call to Review Topline Res...
Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it expects to release topline results from the Phase 2 ALTITUDE-NASH ...
Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split
Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split EDISON, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 4:01 p.m. Eastern Time today, May 10, ...
Hepion Pharmaceuticals to Present Data on Synergistic Effects of Renco...
Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023 EDISON, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented by its Chief Scientific Off...
Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Dis...
Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs EDISON, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, announces the addition of four new internationally recognized thought leaders to its Scientific Advisory Board (“SAB”), effective immediately. The...
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug De...
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development EDISON, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, announces that its Chief Executive Officer, Robert Foster, PharmD, PhD, and its Senior Vice President for Clinical Pharmacology and Analytics, Patric...
Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clin...
Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, announces that its Chief Medical Officer, Todd Hobbs, MD, will be presenting “Rencofilstat (CRV431):...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.